Express Scripts framed its formulary as a response to pharma: “Despite promises to limit price increases, drug makers are trying to game the market by delaying generic competition, blocking access to safe and effective biosimilars, and coyly deferring—not cancelling—list price increases,” it said.
Yesterday, pharmacy benefit manager (PBM) Express Scripts released its National Preferred Formulary Exclusion List Changes for 2019, which will provide access to 3886 medications to the 25 million Americans whose plans use the PBM. There will be 48 new exclusions to the formulary, effective January 1, 2019, including antiretrovirals, growth hormones, and hepatitis C treatments.
Express Scripts framed its formulary as a response to pharma: “Despite promises to limit price increases, drug makers are trying to game the market by delaying generic competition, blocking access to safe and effective biosimilars, and coyly deferring—not cancelling—list price increases,” read the PBM’s statement on the formulary changes, saying that its changes “expose opportunities” to improve affordability and access to medications.
Click here to read more about list price increases.
“Countering drug makers’ high prices includes seizing opportunities for generic and biosimilar drugs, forcing head-to-head competition between brand-drug makers and understanding new or updated FDA indications and studies,” said Everett Neville, RPh, executive vice president of strategy, supply chain, and specialty at Express Scripts in a statement.
PBMs have been making news of late as the Trump administration looks to lower out-of-pocket costs for consumers. Many stakeholders have pointed to the often-undisclosed number of rebates that PBMs receive as a main cause for the high cost of drugs, and HHS has signaled that it may do away with the rebate system altogether.
Meanwhile, drug makers have also been the subject of criticism for allegedly taking part in “pay-for-delay” tactics, in which they reach settlements with biosimilar or generic developers to stave off the launch of a lower-cost product for years. Express Scripts took an opportunity to highlight that controversy in announcing its formulary: “Unfortunately, FDA approval is not assured when drug makers abuse the drug approval system and enter into settlements or otherwise delay the launch of lower-cost competitors, including specialty drugs that treat inflammatory conditions. We remain committed to re-evaluating these therapy classes as soon as competitive products come to market,” said Neville.
In addition to its formulary changes, Express Scripts has also stated that it will be passing on approximately 95% of all pharmaceutical purchase discounts, price reductions, and rebates back to its PBM commercial and health plan clients and their members.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.